Back to Browse Journals » Journal of Asthma and Allergy » Volume 4

Clinical update on the use of biomarkers of airway inflammation in the management of asthma

Authors Wadsworth SJ, Sin DD, Dorscheid DR

Published Date June 2011 Volume 2011:4 Pages 77—86

DOI http://dx.doi.org/10.2147/JAA.S15081

Published 30 June 2011

SJ Wadsworth1,2, DD Sin1,2, DR Dorscheid1,2
1UBC James Hogg Research Centre, Providence Heart and Lung Institute, St Paul's Hospital, Vancouver, Canada; 2Department of Medicine, University of British Columbia, British Columbia, Canada

Abstract: Biological markers are already used in the diagnosis and treatment of cardiovascular disease and cancer. Biomarkers have great potential use in the clinic as a noninvasive means to make more accurate diagnoses, monitor disease progression, and create personalized treatment regimes. Asthma is a heterogeneous disease with several different phenotypes, generally triggered by multiple gene-environment interactions. Pulmonary function tests are most often used objectively to confirm the diagnosis. However, airflow obstruction can be variable and thus missed using spirometry. Furthermore, lung function measurements may not reflect the precise underlying pathological processes responsible for different phenotypes. Inhaled corticosteroids and ß2-agonists have been the mainstay of asthma therapy for over 30 years, but the heterogeneity of the disease means not all asthmatics respond to the same treatment. High costs and undesired side effects of drugs also drive the need for better targeted treatment of asthma. Biomarkers have the potential to indicate an individual's disease phenotype and thereby guide clinicians in their decisions regarding treatment. This review focuses on biomarkers of airway inflammation which may help us to identify, monitor, and guide treatment of asthmatics. We discuss biomarkers obtained from multiple physiological sources, including sputum, exhaled gases, exhaled breath condensate, serum, and urine. We discuss the inherent limitations and benefits of using biomarkers in a heterogeneous disease such as asthma. We also discuss how we may modify our study designs to improve the identification and potential use of potential biomarkers in asthma.

Keywords: asthma, inflammation, airway biomarkers, urinary biomarkers, serum biomarkers

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Enhanced photodynamic leishmanicidal activity of hydrophobic zinc phthalocyanine within archaeolipids containing liposomes [Corrigendum]

Perez AP, Casasco A, Schilrreff P, Defain Tesoriero MV, Duempelmann L, Pappalardo JS, Altube MJ, Higa L, Morilla MJ, Petray P, Romero EL

International Journal of Nanomedicine 2015, 10:169-170

Published Date: 29 December 2014

Clinical utility of asthma biomarkers: from bench to bedside

Vijverberg SJH, Hilvering B, Raaijmakers JA, Lammers JW, Maitland-van der Zee AH, Koenderman L

Biologics: Targets and Therapy 2013, 7:199-210

Published Date: 29 August 2013

Main causes of death among Swedish women born 1914 and 1918: 32-year follow-up of the Population Study of Women in Gothenburg

Hange D, Sigurdsson JA, Björkelund C, Lapidus L, Bengtsson C

International Journal of General Medicine 2012, 5:597-601

Published Date: 12 July 2012

Matched case-control studies: a review of reported statistical methodology

Niven DJ, Berthiaume LR, Fick GH, Laupland KB

Clinical Epidemiology 2012, 4:99-110

Published Date: 27 April 2012

A scalable fabrication process of polymer microneedles

Yang S, Feng Y, Zhang L, Chen N, Yuan W, Jin T

International Journal of Nanomedicine 2012, 7:1415-1422

Published Date: 12 March 2012

Fe3O4/Au magnetic nanoparticle amplification strategies for ultrasensitive electrochemical immunoassay of alfa-fetoprotein

Gan N, Jin H, Li T, Zheng L

International Journal of Nanomedicine 2011, 6:3259-3269

Published Date: 9 December 2011

Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies

Tawara K, Oxford JT, Jorcyk C

Cancer Management and Research 2011, 3:177-189

Published Date: 18 May 2011

Erratum

RA Kurt, K Gündüz

Clinical Ophthalmology 2010, 4:981-982

Published Date: 6 September 2010

Recommendation for optimal management of severe refractory asthma

Jaymin B Morjaria, Riccardo Polosa

Journal of Asthma and Allergy 2010, 3:43-56

Published Date: 26 July 2010

Alogliptin: a new addition to the class of DPP-4 inhibitors

Radha Andukuri, Andjela Drincic, Marc Rendell

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009, 2:117-126

Published Date: 21 July 2009